Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
Earlier this month, Alkermes plc announced that the FDA granted Breakthrough Therapy designation to alixorexton, its oral selective orexin 2 receptor agonist, for narcolepsy type 1 based on positive ...
Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...
Paul P. Doghramji, MD, discusses the underdiagnosis of narcolepsy especially among younger individuals and how clinicians can address this.
For some, naps are restorative, but for others, they derail a whole day—and night. Sleep doctors share the best way to take a ...
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...
In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
Harmony Biosciences expects its narcolepsy treatment Wakix to reach a major sales milestone in 2026, but the Plymouth Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback